PETX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PETX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Aratana Therapeutics's share price is $4.92. Aratana Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2019 was $0.81. Hence, Aratana Therapeutics's PS Ratio for today is 6.04.
The historical rank and industry rank for Aratana Therapeutics's PS Ratio or its related term are showing as below:
Aratana Therapeutics's Revenue per Sharefor the three months ended in Mar. 2019 was $0.15. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2019 was $0.81.
The historical data trend for Aratana Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aratana Therapeutics Annual Data | |||||||||||||||||
Trend | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | |||||||||
PS Ratio | Get a 7-Day Free Trial | 712.80 | 265.71 | 6.48 | 8.46 | 8.15 |
Aratana Therapeutics Quarterly Data | ||||||||||||||||||||
Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | |
PS Ratio | Get a 7-Day Free Trial | 7.24 | 7.24 | 6.52 | 8.15 | 4.42 |
For the Biotechnology subindustry, Aratana Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Aratana Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Aratana Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Aratana Therapeutics's PS Ratio for today is calculated as
PS Ratio | = | Share Price | / | Revenue per Share (TTM) |
= | 4.92 | / | 0.814 | |
= | 6.04 |
Aratana Therapeutics's Share Price of today is $4.92.
Aratana Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.81.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PS Ratio | = | Market Cap | / | Revenue |
The Revenue here is for the trailing 12 months.
Aratana Therapeutics (NAS:PETX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.
Be Aware
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Thank you for viewing the detailed overview of Aratana Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Roche Robert P Jr | director | 41 MOORES ROAD FRAZER PA 19355 |
Vort John Vander | director | C/O MPM ASSET MANAGEMENT, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116 |
Lowell W Robinson | director | 470 WEST END AVENUE, NEW YORK NY 10024 |
Wendy L Yarno | director | |
David L Brinkley | director | 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Merilee Raines | director | IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092 |
Kevin Kotler | 10 percent owner | C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Broadfin Capital, Llc | 10 percent owner | 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Broadfin Healthcare Master Fund Ltd | 10 percent owner | C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108 |
Craig A. Barbarosh | director | 3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305 |
Hockaday Irvine O Jr | director | SPRINT NEXTEL CORPORATION, 2001 EDMUND HALLEY DRIVE, RESTON VA 20191 |
Craig A Tooman | director, officer: President and CEO | |
Peter Steven St | director, officer: PRESIDENT AND CEO | MPM CAPITAL, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116 |
Laura Brege | director | C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608 |
Jay Lichter | director | C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211 |
From GuruFocus
By PRNewswire PRNewswire • 11-02-2018
By Marketwired Marketwired • 06-25-2019
By PRNewswire PRNewswire • 06-01-2018
By PRNewswire PRNewswire • 02-04-2019
By PRNewswire PRNewswire • 04-26-2019
By PRNewswire PRNewswire • 05-07-2019
By PRNewswire PRNewswire • 01-18-2019
By PRNewswire PRNewswire • 10-22-2018
By Marketwired Marketwired • 04-27-2019
By Marketwired Marketwired • 05-09-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.